First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer

By News Health
5 hours Ago

(MedPage Today) — First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib (Lenvima) or sorafenib (Nexavar) for patients with unresectable hepatocellular carcinoma (HCC), the…

Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/115597

Author :

Publish date : 2025-05-15 15:43:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

MD Reacts to RFK Jr. Hearing; The Roast of Casey Means; 'Unhinged' Healthcare

GLP-1s and Acute Pancreatitis; Yoga for IBS? MASLD Tied to Early-Onset Colon Cancer

Matt Hancock ignored call to test all NHS staff, Covid inquiry hears

In a First, CRISPR Used to Treat Infant With Ultra-Rare Disease

Missouri Lawmakers Approve Referendum to Repeal Abortion-Rights Amendment

No Barrett’s Survival Benefit With Regular Surveillance